Oryzon Genomics S.A. (ORYZF)
OTCMKTS · Delayed Price · Currency is USD
3.600
+0.240 (7.14%)
At close: Jan 27, 2026
Oryzon Genomics Employees
Oryzon Genomics had 47 employees as of June 30, 2025. The number of employees did not change since the number was reported on December 31, 2024.
Employees
47
Change
n/a
Growth
n/a
Revenue / Employee
$183,702
Profits / Employee
-$68,800
Market Cap
290.97M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 47 | 0 | - |
| Dec 31, 2024 | 47 | 1 | 2.17% |
| Dec 31, 2023 | 46 | 2 | 4.78% |
| Dec 31, 2022 | 44 | 0 | - |
| Dec 31, 2021 | 44 | 1 | 1.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
Oryzon Genomics News
- 7 weeks ago - ORYZON Expands Global Patent Protection for Iadademstat with Grant Decision in Japan Covering Combinations with PD-1/PD-L1 Inhibitors - GlobeNewsWire
- 2 months ago - ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting - GlobeNewsWire
- 3 months ago - ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025 - GlobeNewsWire
- 3 months ago - ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease - GlobeNewsWire
- 3 months ago - ORYZON to Participate in Upcoming Events in November - GlobeNewsWire
- 4 months ago - ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder - GlobeNewsWire
- 4 months ago - ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors - GlobeNewsWire
- 5 months ago - ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant - GlobeNewsWire